Literature DB >> 29106353

Testing direct oral anticoagulants: embedding in structured long-term care.

Hugo Ten Cate1,2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29106353      PMCID： PMC6125238          DOI： 10.2450/2017.0197-17

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  11 in total

1.  Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors.

Authors:  Gregory Y H Lip; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2015-12-01       Impact factor: 24.094

2.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

3.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

Review 4.  Laboratory Assessment of Direct Oral Anticoagulants.

Authors:  Jonathan Douxfils; Robert C Gosselin
Journal:  Semin Thromb Hemost       Date:  2017-03-01       Impact factor: 4.180

Review 5.  Evolving use of new oral anticoagulants for treatment of venous thromboembolism.

Authors:  Calvin H Yeh; Peter L Gross; Jeffrey I Weitz
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

6.  Real-world variability in dabigatran levels in patients with atrial fibrillation.

Authors:  N C Chan; M Coppens; J Hirsh; J S Ginsberg; J I Weitz; T Vanassche; J D Douketis; S Schulman; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2015-01-28       Impact factor: 5.824

7.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

8.  [Prevalence of atrial fibrillation, treatment eligibility and consumption of oral anticoagulants in Italian Local Health Authorities: impact of non-vitamin K antagonist oral anticoagulants].

Authors:  Felicita Andreotti; Daniela D'Angela; R Letizia Mancusi; Federico Spandonaro
Journal:  G Ital Cardiol (Rome)       Date:  2017-03

9.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; David A Morrow; Sabina A Murphy; Julia F Kuder; Naveen Deenadayalu; Petr Jarolim; Joshua Betcher; Minggao Shi; Karen Brown; Indravadan Patel; Michele Mercuri; Elliott M Antman
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

10.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Hans-Christoph Diener; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2015-08-31       Impact factor: 5.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.